Evidence map›Paper›PMID 42006277›Full record

ArticleJTO clinical and research reports2026

Mutation-Specific Response to Ramucirumab in

Kazuto Nishio, Kazuko Sakai, Makoto Nishio, Takashi Seto, Carla Visseren-Grul, Michelle Carlsen, Sotaro Enatsu, Tomoko Matsui, Kazuhiko Nakagawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kazuto NishioDepartment of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
Kazuko SakaiDepartment of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
Makoto NishioDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Takashi SetoDepartment of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Carla Visseren-GrulEli Lilly Netherlands, Utrecht, The Netherlands.
Michelle CarlsenEli Lilly and Company, Indianapolis, Indiana.
Sotaro EnatsuEli Lilly Japan K.K., Kobe, Japan.
Tomoko MatsuiEli Lilly Japan K.K., Kobe, Japan.
Kazuhiko NakagawaDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A previous analysis of the RELAY phase 3 liquid biopsy addendum demonstrated suppressed Methods: Patients were randomized 1:1 to RAM plus ERL or PL plus ERL. Liquid biopsy samples were collected at baseline, during treatment, and at post-progression 30-day follow-up. Results: Within both ex19del and L858R subgroups, Conclusions: This updated analysis revealed differences in total cfDNA concentration and T790M mutation rates between ex19del and L858R. RAM plus ERL may exhibit greater antitumor effects on L858R, supporting the favorable survival benefits observed previously in patients with a L858R.

Indexed as

CarcinomacfDNA fragmentsCirculating tumor DNAEGFR-activating mutation allelesLiquid biopsynon–small cell lung

Identifiers

PMID42006277
PMCPMC13091193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.